La startup HAYA recauda $65 millones para iluminar el genoma oscuro con un fármaco líder para la insuficiencia cardíaca.
Many drugs currently available and in development target proteins, but this approach has its limitations, according to Samir Ounzain, co-founder and CEO of HAYA Therapeutics. Ounzain argues that proteins are not the root cause of disease; instead, it is the response of cells to their environment that drives disease. This response is regulated by a … Leer más